Comparing timing of embryo transfer in women with recurrent implantation failure
A Randomized Controlled Trial Comparing Frozen Embryo Transfer Guided by Endometrial Receptivity Analysis Vs Standard Timing in Patients with Recurrent Implantation Failure
This study is testing if timing frozen embryo transfers based on a special test can help women with repeated implantation failures get pregnant more successfully than using the usual timing methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 734 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06762626 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of endometrial receptivity analysis (ERA) in guiding the timing of frozen embryo transfers for women experiencing recurrent implantation failure (RIF). Participants will first undergo an endometrial biopsy to assess receptivity and will then be randomly assigned to either an ERA-guided transfer group or a standard timing group. The goal is to determine if timing the transfer based on ERA results can improve pregnancy rates compared to traditional methods. The trial is multicenter and double-blind, involving multiple hospitals across China.
Who should consider this trial
Good fit: Ideal candidates are women under 40 years old with recurrent implantation failure who have at least one high-quality frozen blastocyst.
Not a fit: Patients with recurrent pregnancy loss, known chromosomal abnormalities, or certain uterine pathologies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly increase pregnancy rates for women with recurrent implantation failure.
How similar studies have performed: While there is limited randomized controlled trial data on ERA's effectiveness in this context, similar approaches have shown promise in improving outcomes in other fertility-related studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Women with recurrent implantation failure 2. Women aged \< 40 years 3. Body mass index of women between 18.5 (inclusive) and 30 (exclusive) kg/m² 4. Women with at least one high quality frozen blastocyst (BB grade or above) and planning to undergo a single blastocyst transfer 5. Women who will give written informed consent Exclusion Criteria: 1. Women with recurrent pregnancy loss (3 or more biochemical or spontaneous miscarriages) 2. Either partner with known chromosomal abnormalities including balanced translocations 3. Women undergoing preimplantation genetic testing 4. Women with endometrial thickness \< 7 mm in the IVF cycle 5. Women with a confirmed diagnosis of stage III-IV endometriosis or adenomyosis affecting uterine cavity morphology 6. Women with a confirmed diagnosis of antiphospholipid syndrome 7. Pathologies affecting the uterine cavity, including polyps, submucosal fibroids, intramural fibroids \> 4 cm, or hydrosalpinx
Where this trial is running
Hong Kong
- The University of Hong Kong — Hong Kong, China (Recruiting)
Study contacts
- Study coordinator: Ernest HY Ng, MD
- Email: nghye@hku.hk
- Phone: +85222553400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.